The recent negative factor is the Eli Lilly earnings report on April 30. Lilly's management is sure to hype their oral and injectable drugs. It's another chance to add to positions.$Novo Nordisk AS(NVO.US)
Hold onto $Novo Nordisk AS(NVO.US) with the positive catalyst of the May 6th earnings report combined with the European Congress of Endocrinology (ECE) from May 9th to 12th. Additionally, the global endocrinology congress is in Japan in early June $Novo Nordisk AS(NVO.US)
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
